Products

QUIBIM Precision Prostate (qp-Prostate)
QUIBIM S.L.
Oncology AI
QUIBIM Precision Prostate (qp-Prostate) is an FDA-cleared AI tool that enhances prostate MRI interpretation through automated segmentation, AI-driven lesion detection, and PI-RADS compliant reporting, aiming to improve diagnostic accuracy and streamline radiology workflows.
QP-Brain®
Quibim S.L.
Neurology AI
QP-Brain® is an AI-powered medical imaging software by Quibim S.L. that provides quantitative analysis of brain MRI scans for early detection and monitoring of neurodegenerative diseases like Alzheimer's and MS. It automates the quantification of brain structures and white matter hyperintensities, integrating directly with PACS for efficient radiological reporting.
QP-Prostate® CAD
Quibim S.L.
Oncology AI
QP-Prostate® CAD by Quibim S.L. is an FDA-cleared AI-powered software for the detection and diagnosis of clinically significant prostate cancer using MRI, enhancing diagnostic accuracy and streamlining radiology workflows.

See all 3 products →

About Quibim S.L.

Quibim S.L. is a leading global health technology company that specializes in transforming medical images into actionable insights using artificial intelligence (AI) and advanced computational models. Their core mission is to revolutionize precision medicine by extracting quantitative imaging biomarkers from routine medical images such as MRI, CT, and PET scans, alongside molecular and clinical data. This approach aims to provide physicians with additional, objective information beyond qualitative radiological assessments, enabling more accurate diagnoses and personalized treatment strategies.

For physicians, Quibim’s technology offers a cloud-based platform that manages, indexes, stores, and harmonizes imaging data, integrating with electronic health records. The platform provides automated tools for analyzing specific organ systems, including the prostate, brain, liver, breast, and lung, facilitating the calculation of volumetric data and the identification of imaging patterns to assist in disease classification and monitoring. Their products, such as QP-Prostate®, QP-Brain®, and QP-Liver®, are regulatory-cleared medical devices designed to streamline clinical practice, enhance diagnostic accuracy, and optimize patient monitoring. Quibim also partners with biopharmaceutical companies to accelerate drug development programs by identifying suitable candidates for clinical studies, monitoring treatment response, and assessing toxicity and adverse events through AI models.

Focus Areas

AI-powered medical imaging imaging biomarkers precision medicine oncology neurology immunology metabolic disorders prostate cancer brain atrophy liver diseases multi-omics data analysis radiomics drug development clinical trials digital twins

Business Intelligence

TechnologyCloud-based, AI-powered imaging platform (Quibim Precision®), QP-Insights (data management, harmonization, multi-omics, EHR integration), tissue-agnostic, deep learning, radiomics, ISO 27001:2022 certified, HIPAA and GDPR compliant, Microsoft Azure cloud platform

What Physicians Need to Know

AI-Powered Medical Imaging & Biomarkers
Quibim specializes in transforming medical images (MRI, CT, PET) into quantitative, actionable insights using AI. They develop imaging biomarkers to detect pathologies, predict outcomes, and monitor treatment effectiveness across various diseases.
Precision Medicine & Drug Development
The company leverages AI to support precision medicine by enabling earlier disease diagnosis, predicting patient response to treatments, and developing personalized therapeutic approaches. For drug development, Quibim's platform accelerates clinical trials, identifies suitable candidates, stratifies patients, and monitors toxicity and adverse events.
Oncology & Specific Disease Areas
Quibim has a strong focus on oncology, including prostate cancer and lymphoma, and extends its expertise to neurology (e.g., brain atrophy, neurodegenerative diseases), immunology (e.g., rheumatic diseases, immunotherapy response), and metabolic disorders.
Multi-omics Data Analysis & Radiomics
Their platform integrates imaging data with molecular and clinical multi-omics data to provide a comprehensive understanding of disease and patient trajectory, going beyond isolated measurements. Radiomics is at the core of their platform, extracting detailed quantitative features from images.
Digital Twins & Clinical Trials
Quibim contributes to clinical trials by creating virtual patient cohorts through imaging biomarkers (synthetic control arms) and optimizing trial recruitment through pre-approval patient stratification.
Physician Tip

For physicians, Quibim's solutions offer automated analysis of imaging biomarkers, providing accurate and reproducible results within minutes. The platform, such as QP-Prostate, integrates seamlessly with PACS systems, streamlining workflows and providing precise, quantitative information for standardized decision-making and PI-RADS compliance. This allows for more accurate diagnoses by extracting additional, often subtle, information from existing imaging samples, supporting real-time individualized patient decisions and improving patient outcomes.

Quibim's QP-Insights® platform is fully web-based and designed for centralized management, storage, and processing of imaging, multi-omics, and clinical data. It supports integration with local PACS systems via QP-Link® for automatic transfer of images and reports, delivering structured quantitative reports directly to PACS. The platform ensures end-to-end data protection with encryption, de-identification of patient data, and compliance with ISO 27001, HIPAA, and GDPR standards.

Products by Quibim S.L.

3 products in the directory

QUIBIM Precision Prostate (qp-Prostate)
QUIBIM S.L.
Oncology AI
QUIBIM Precision Prostate (qp-Prostate) is an FDA-cleared AI tool that enhances prostate MRI interpretation through automated segmentation, AI-driven lesion detection, and PI-RADS compliant reporting, aiming to improve diagnostic accuracy and streamline radiology workflows.
QP-Brain®
Quibim S.L.
Neurology AI
QP-Brain® is an AI-powered medical imaging software by Quibim S.L. that provides quantitative analysis of brain MRI scans for early detection and monitoring of neurodegenerative diseases like Alzheimer's and MS. It automates the quantification of brain structures and white matter hyperintensities, integrating directly with PACS for efficient radiological reporting.
QP-Prostate® CAD
Quibim S.L.
Oncology AI
QP-Prostate® CAD by Quibim S.L. is an FDA-cleared AI-powered software for the detection and diagnosis of clinically significant prostate cancer using MRI, enhancing diagnostic accuracy and streamlining radiology workflows.

What the Web Says

Quibim S.L. is a European health-tech company specializing in AI-driven precision medicine, extracting quantitative imaging biomarkers from medical images to detect disease patterns and monitor biological systems. Their platform integrates AI-powered solutions and data harmonization tools for managing, integrating, storing, and analyzing multi-omics data, with a core focus on imaging. Quibim's products, such as QP-Prostate®, QP-Brain, and QP-Liver, are designed to integrate into hospital radiology workflows via PACS connections, providing AI-assisted diagnostic support.

Overall: Positive

Strengths

  • Comprehensive all-in-one platform for multi-omics data with imaging at its core.
  • AI-powered solutions and data harmonization tools ensure uniform image quality.
  • Products like QP-Prostate, QP-Brain, and QP-Liver are designed for seamless integration into hospital radiology workflows via PACS.
  • Robust data security with encryption and ISO 27001 certification.
  • Patient data privacy with complete de-identification of patient data.
  • Company culture is described as scientific, collaborative, innovative, and mission-driven, with an emphasis on improving patient outcomes.

Limitations

  • No specific negative product or employer reviews were found on the searched platforms (G2, Glassdoor, Capterra, Reddit).
  • Recruitment is selective, especially for technical and strategic roles.
  • Limited opportunity for hands-on experience or trials directly through platforms like Capterra.

Based on reviews from: The Silicon Review, EUJobs, QMENTA vs. Quibim: A Strategic Comparison of Medical Imaging AI Platforms, BioWorld, Capterra, G2, Reddit

Last updated: 2026-10-19

Videos

News, demos, and interviews about Quibim S.L..

Loading videos...

Videos load interactively. If none appear, search YouTube for Quibim S.L. →

View all on YouTube

Press & Coverage

Business Wire
Quibim Announces $50 Million in Series A Financing, led by Asabys and Buenavista, to Revolutionize Precision Medicine with AI-Powered Imaging Biomarkers
Quibim closed a $50 million Series A financing round led by Asabys and Buenavista to expand its product pipeline, foundational AI models, and accelerate global commercial growth in precision medicine with AI-powered imaging biomarkers.
2025-01
Quibim Website
Quibim launches CE and UKCA-marked QP-Breast®, the first AI tool to detect breast cancer via MRI in Europe and the UK
Quibim launched QP-Breast®, an AI tool for breast cancer detection via MRI, which has received CE and UKCA marks, making it available in Europe and the UK.
2026-07
Quibim Website
QP-Prostate® Receives Health Canada Licence, Expanding Quibim's Reach to Canada
Quibim's QP-Prostate® has received a Health Canada Licence, allowing the company to expand its reach into the Canadian market.
2026-06
Quibim Website
Quibim, the Only Healthtech Selected by New York for Its Strategic AI Program
Quibim was selected as the only healthtech company to join New York City's strategic AI program, the NYC AI International Landing Pad, to accelerate its U.S. expansion.
2026-05
BioWorld
Quibim launches QP-Brain software after regulatory clearance
Quibim launched its AI-based software QP-Brain, designed for early-stage neurodegenerative disease detection, after receiving U.S. FDA 510(k) clearance, as well as CE and UKCA marks.
2024-01
Quibim Website
Quibim receives FDA 510(k) Clearance for QP-Prostate, a new AI solution for prostate MRI analysis
Quibim announced the launch of QP-Prostate, its AI-based prostate MRI solution, after receiving 510(k) clearance from the US FDA, aiming to increase diagnostic accuracy and early prostate cancer detection.
2025-03
Quibim Website
Quibim Unveils Four Oncology Imaging Publications at ASCO 2025
Quibim announced the publication of four scientific contributions at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing advances in imaging biomarkers, AI, and non-invasive companion diagnostics for personalized oncology care.
2025-05
Quibim Website
Quibim launches a platform to deploy imaging-based algorithms to accelerate drug development programs
Quibim launched QP-Insights, a new web platform designed to manage, store, and quantitatively analyze medical images and other clinical data to accelerate drug development programs.
2024-02

Frequently Asked Questions

Quibim S.L. provides AI-powered imaging biomarkers for various conditions, including prostate cancer and brain atrophy. Their solutions are designed to assist in the early detection, characterization, and monitoring of diseases, offering quantitative insights from medical images to support precision medicine in oncology and neurology.
Quibim S.L. is committed to regulatory compliance, with several of its products being CE marked as medical devices. They adhere to stringent quality management systems to ensure their AI algorithms and imaging biomarkers meet the necessary standards for safety and efficacy in clinical settings.
Quibim S.L.'s platform, QP-DISCOVERY, is designed for seamless integration with existing hospital systems, including PACS and EMRs, to streamline workflows and data access. They offer comprehensive technical support, including implementation assistance, training, and ongoing maintenance to ensure smooth operation and user proficiency.
Quibim S.L. utilizes radiomics and multi-omics data analysis to extract deep, quantitative insights from medical images, which can be correlated with genomic, proteomic, and other patient data. This integrated approach helps in identifying novel biomarkers, stratifying patients for clinical trials, and accelerating drug development by providing a more comprehensive understanding of disease mechanisms and treatment response.
Quibim S.L.'s approach to 'digital twins' involves creating virtual representations of patients based on their medical imaging and multi-omics data. This allows for personalized disease modeling, prediction of treatment responses, and optimization of therapeutic strategies, ultimately enhancing precision medicine and individualized patient management within your institution.
Quibim S.L. offers flexible pricing models tailored to the specific needs and scale of healthcare providers, though exact details would require direct consultation. They typically provide various subscription options and licensing agreements for their AI-powered imaging analysis platform and biomarker solutions.
Quibim S.L. actively collaborates with leading pharmaceutical companies and research institutions globally, fostering advancements in areas like oncology, neurology, immunology, and metabolic disorders. These partnerships enable them to validate their imaging biomarkers, develop new AI algorithms, and integrate their technology into drug development pipelines and clinical trials, ultimately expanding their offerings and scientific impact.

Investors

Who's funded Quibim S.L..

Comparisons

QP-Prostate® CAD vs TumorSight Viz
Quantib Prostate vs QUIBIM Precision Prostate (qp-Prostate)

For a physician evaluating AI tools for prostate MRI interpretation, Quantib Prostate and QUIBIM Precision Prostate (qp-Prostate) both offer FDA-cleared solutions to enhance diagnostic workflows. Quantib Prostate excels in providing advanced tools for segmentation, PI-RADS scoring, and standardized reporting, with a strong emphasis on visual support for PI-RADS v.2.1 and kinetic curve representation. It is […]

QP-Prostate® CAD vs QUIBIM Precision Prostate (qp-Prostate)

When considering AI tools for prostate MRI interpretation, physicians have two options from Quibim S.L.: QP-Prostate® CAD and QUIBIM Precision Prostate (qp-Prostate). Both are FDA-cleared and aim to enhance diagnostic accuracy and streamline radiology workflows for prostate cancer detection. Both tools offer automated prostate segmentation, AI-driven lesion detection, and PI-RADS compliant reporting, along with AI-QUAL™ […]

QUIBIM Precision Prostate (qp-Prostate) vs ProstatID

When choosing between QUIBIM Precision Prostate (qp-Prostate) and ProstatID, physicians should consider their existing infrastructure and specific workflow needs. qp-Prostate excels in comprehensive prostate MRI interpretation, offering automated segmentation, AI-driven lesion detection, and PI-RADS compliant reporting. It also provides advanced features like automated image quality assessment (AI-QUAL™) and support for fusion and focal therapy planning. […]

Related Companies

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

NTL Healthcare is a South Korean AI-powered women’s health company specializing in cervical cancer screening and diagnostics. The company has a history dating back to 1996 when it first introduced an analog cervical cancer reading system, Cervicography, to Korea. Since then, NTL Healthcare has evolved its technology, developing the world’s first remote uterine cervical cancer […]

Lumonus is a healthcare technology company that specializes in AI-powered solutions for cancer care, particularly in radiation oncology. The company’s core offering is the Lumonus AI platform, a digital oncology system with AI-native clinical infrastructure designed to automate and orchestrate critical oncology workflows. This platform aims to enhance the quality and speed of care delivery […]

Koios Care is a neurology-focused digital medicine company based in Antwerp, Belgium, specializing in AI-powered platforms. The company aims to revolutionize the management of neurological and chronic conditions, with an initial focus on Parkinson’s Disease. Koios Care’s platform utilizes everyday devices like smartphones and smartwatches to passively collect and analyze data, transforming it into objective, […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.